Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF)
Sponsor: National Cancer Institute (NCI)
Listed as NCT00669734, this observational or N/A phase trial focuses on Locally Advanced Pancreatic Adenocarcinoma and Pancreatic Acinar Cell Carcinoma and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 37 times since 2010, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To determine the tolerability of delivering two standard doses of the PANVAC-F (fowlpox) (falimarev) vaccine administered intratumorally in conjunction with subcutaneous injections of PANVAC-V (vaccinia) (inalimarev) followed by PANVAC-F (fowlpox) in conjunction with rH-GM-CSF (sargramostim) versus (vs.) subcutaneously injected PANVAC-V or PANVAC-F in conjunction with rH-GM-CSF in patients with incurable pancreatic cancer based on local unresectability or with small volume metastases. SECONDARY OBJECTIVES: I. To assess the toxicity of the vaccine injections. II. To assess evidence of tumor response by imaging and tumor marker response. III. To assess gene transfer to pancreatic tissue. IV. To assess immunologic response to PANVACTM. OUTLINE: This is a dose-escalation study of falimarev. Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine subcutaneously (SC) on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of...
PRIMARY OBJECTIVES:
I. To determine the tolerability of delivering two standard doses of the PANVAC-F (fowlpox) (falimarev) vaccine administered intratumorally in conjunction with subcutaneous injections of PANVAC-V (vaccinia) (inalimarev) followed by PANVAC-F (fowlpox) in conjunction with rH-GM-CSF (sargramostim) versus (vs.) subcutaneously injected PANVAC-V or PANVAC-F in conjunction with rH-GM-CSF in patients with incurable pancreatic cancer based on local unresectability or with small volume metastases.
SECONDARY OBJECTIVES:
I. To assess the toxicity of the vaccine injections. II. To assess evidence of tumor response by imaging and tumor marker response. III. To assess gene transfer to pancreatic tissue. IV. To assess immunologic response to PANVACTM.
OUTLINE: This is a dose-escalation study of falimarev.
Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine subcutaneously (SC) on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
Patients undergo biopsy periodically for correlative studies.
After completion of study treatment, patients are followed every 3 months.
Status Flow
Change History
37 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Phase: PHASE1 → None
-
Nov 2025 — Apr 2026 [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 32 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — May 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
May 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Dec 2022 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
-
May 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1
-
Mar 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Jan 2020 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This phase I trial studies the side effects and best dose of vaccine therapy when given together with sargramostim in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy directly into the tumor together with sargramostim may cause a stronger immune response and kill more tumor cells.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .